Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. 1990

A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
Divisione di Oncologia Medica, U.S.S.L. 21 Padova, Italy.

A total of 21 untreated patients (5 males, 16 females; median age, 55 years; range, 28-72) with advanced measurable colorectal carcinoma were treated with an association of 5-fluorouracil (1000 mg/weekly) and alpha-2 interferon (three times a week s.c.: 6 x 10(6) U in the 1st month, 9 x 10(6) U in the 2nd month, 12 x 10(6) U in the 3rd month and then 18 x 10(6) U) until maximum response or progression of disease. Sites of disease involved liver in 10 patients, lung in 6, supraclavicular lymph nodes in 3, skin in 1, abdomen in 4, and vagina in 1 patient. Nine responses (42.8%) were documented (4 complete and 5 partial) with metastases confined to the liver, lung, nodes and skin. Median duration of response was 11 months (range, 4-17+) and median survival was 10 months (range, 2-17+). Side effects (fever, flu-like syndrome and leukopenia) required a dose reduction of 5-fluorouracil in 8 patients and interferon in 2 patients.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
August 1995, Cancer,
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
March 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
April 1989, Journal of chemotherapy (Florence, Italy),
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
March 2001, British journal of cancer,
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
December 1993, Cancer,
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
January 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
December 1996, British journal of cancer,
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
January 1992, European journal of cancer (Oxford, England : 1990),
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
August 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
A Fornasiero, and O Daniele, and C Ghiotto, and S M Aversa, and P Morandi, and M V Fiorentino
June 1995, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!